Enliven Therapeutics (ELVN) Change in Accured Expenses (2019 - 2026)

Enliven Therapeutics has disclosed Change in Accured Expenses across 8 years of filings, most recently posting -$4.5 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.5 million, down 78.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 865.84% YoY), and the FY2025 annual result was -$496000.0, down 100.0% from the prior year.
• Change in Accured Expenses came in at -$4.5 million for Q1 2026 at Enliven Therapeutics, down from $1.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.8 million in Q4 2023 to a low of -$4.5 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $387000.0 (2022), against an average of $239294.1.
• Peak annual rise in Change in Accured Expenses reached 1098.19% in 2023, while the deepest fall reached 897.2% in 2023.
• Enliven Therapeutics' Change in Accured Expenses stood at $663000.0 in 2022, then soared by 621.27% to $4.8 million in 2023, then plunged by 126.85% to -$1.3 million in 2024, then jumped by 191.59% to $1.2 million in 2025, then slumped by 479.68% to -$4.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.5 million (Q1 2026), $1.2 million (Q4 2025), and $814000.0 (Q3 2025), per Business Quant data.